By Michael Gwarisa For decades, scientists have battled the elusive human immunodeficiency virus (HIV), whose ability to mutate and develop resistance has defeated one vaccine candidate after another Now, a groundbreaking clinical trial under way in Zimbabwe and South Africa aims to outsmart the virus by targeting its most vulnerable, unchanging parts The investigational vaccine, known scientifically as the Gorilla Adenovirus Vectored HIV Networked Epitopes Vaccine (GRAdHIVNE1), is designed to hit HIV where it hurts most: regions critical to its structure and function, making it harder for the virus to…
Source: Health Times
All Zim News
All Zim News is a central hub for all things Zimbabwean, curating news from across the country so no story is missed Alongside aggregation, our team of nationwide reporters provides real-time, on-the-ground coverage
Stay informed and connected — reach us at admin@allzimnews.com.
Source: Healthtimes
